Soleno to Launch $200M Stock Offering

Soleno Therapeutics (NASDAQ:SLNO) has announced its intent to offer and sell $200 million of common stock in a public offering. Underwriters will also be granted an option to purchase up to an additional $30 million of shares.

Goldman Sachs and Guggenheim Securities will manage the offering. Soleno plans to use the proceeds to fund the commercialization of VYKAT™ XR, which is an approved therapy for hyperphagia in Prader-Willi syndrome. Funds will also support EU regulatory activities, research and development, and general corporate purposes.

The shares will be offered via a registration statement on Form S-3ASR, which was previously filed with the SEC. The public offering is subject to market conditions, and there is no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

VYKAT XR, a once-daily oral treatment, is Soleno’s first commercial product. It addresses hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome.

This information contains forward-looking statements that are subject to risks, uncertainties, and assumptions. Soleno does not plan to update or revise any forward-looking statements.